Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease

American Journal of Neuroradiology

Volumn 36, Issue 6, 2015, Pages 1102-1108

  Murakami, Y ^a   Kakeda, S ^a   Watanabe, K ^a   Ueda, I ^a   Ogasawara, A ^a   Moriya, J ^a   Ide, S ^a   Futatsuya, K ^a   Sato, T ^a   Okada, K ^b   Uozumi, T ^b   Tsuji, S ^b   Liu, T ^c   Wang, Y ^c   Korogi, Y ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Cornell University ^*  (United States)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAIN MAPPING; BRAIN REGION; CAUDATE NUCLEUS; GLOBUS PALLIDUS; IMAGE ANALYSIS; MAGNETISM; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; QUANTITATIVE SUSCEPTIBILITY MAPPING; RADIOLOGIST; RECEIVER OPERATING CHARACTERISTIC; RED NUCLEUS; RETROSPECTIVE STUDY; SIGNAL NOISE RATIO; SUBSTANTIA NIGRA; YOUDEN INDEX; AGED; BRAIN; CASE CONTROL STUDY; COMPUTER ASSISTED DIAGNOSIS; FEMALE; HUMAN; IMAGE ENHANCEMENT; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

IRON;

AGED; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84930975150     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A4260     Document Type: Article

References (47)

1. Caslake R, Moore JN, Gordon JC, et al. Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. J Neurol Neurosurg Psychiatry 2008;79:1202-07
2. Drayer BP, Olanow W, Burger P, et al. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986;159:493-98
3. Bizzi A, Brooks RA, Brunetti A, et al. Role of iron and ferritin in MR imaging of the brain: a study in primates at different field strengths. Radiology 1990;177:59-65
4. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-36
5. Griffiths PD, Dobson BR, Jones GR, et al. Iron in the basal ganglia in Parkinson's disease: an in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999; 122(pt 4):667-73
6. Wang Y. Principles of Magnetic Resonance Imaging: Physics Concepts, Pulse Sequences, and Biomedical Applications. https://www.createspace.com: CreateSpace Independent Publishing Platform; 2012
7. Ordidge RJ, Gorell JM, Deniau JC, et al. Assessment of relative brain iron concentrations using T2-weighted and T2∗-weighted MRI at 3 Tesla. Magn Reson Med 1994;32:335-41
8. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:1-25
9. Gorell JM, Ordidge RJ, Brown GG, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138-43
10. Graham JM, Paley MN, Grunewald RA, et al. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000;123(pt 12):2423-31
11. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411-17
12. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257:455-62
13. Yao B, Li TQ, Gelderen P, et al. Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. Neuroimage 2009;44:1259-66
14. Wang S, Lou M, Liu T, et al. Hematoma volume measurement in gradient echo MRI using quantitative susceptibility mapping. Stroke 2013;44:2315-17
15. Ogawa S, Menon RS, Tank DW, et al. Functional brain mapping by blood oxygenation level-dependent contrast magnetic-resonanceimaging: a comparison of signal characteristics with a biophysical model. Biophys J 1993;64:803-12
16. Davis TL, Kwong KK, Weisskoff RM, et al. Calibrated functional MRI: mapping the dynamics of oxidative metabolism. Proc Natl Acad Sci U S A 1998;95:1834-39
17. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissue: the static dephasing regime. Magn Reson Med 1994;32:749-63
18. de Rochefort L, Liu T, Kressler B, et al. Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194-206
19. Liu J, Liu T, de Rochefort L, et al. Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. Neuroimage 2012;59:2560-68
20. Liu T, Wisnieff C, Lou M, et al. Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping. Magn Reson Med 2013;69:467-76
21. Bilgic B, Pfefferbaum A, Rohlfing T, et al. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012;59:2625-35
22. Deistung A, Schafer A, Schweser F, et al. Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R-2∗-imaging at ultra-high magnetic field strength. Neuroimage 2013;65:299-314
23. Langkammer C, Liu T, Khalil M, et al. Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551-59
24. Lotfipour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012;35:48-55
25. Liu T, Surapaneni K, Lou M, et al. Cerebral microbleeds: burden assessment by using quantitative susceptibility mapping. Radiology 2012;262:269-78
26. Liu T, Khalidov I, de Rochefort L, et al. A novel background field removal method for MRI using projection onto dipole fields (PDF). NMR Biomed 2011;24:1129-36
27. Kressler B, de Rochefort L, Liu T, et al. Nonlinear regularization for per voxel estimation of magnetic susceptibility distributions from MRI field maps. IEEE Trans Med Imaging 2010;29:273-81
28. Pauling L, Coryell CD. The magnetic properties and structure of hemoglobin, oxyhemoglobin and carbonmonoxyhemoglobin. Proc Natl Acad Sci U S A 1936;22:210-16
29. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35
30. Martin WR. Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat Disord 2009; 15(suppl 3):S215-18
31. Du G, Lewis MM, Shaffer ML, et al. Serum cholesterol and nigrostriatal R2∗values in Parkinson's disease. PloS One 2012;7:e35397
32. Rossi M, Ruottinen H, Elovaara I, et al. Brain iron deposition and sequence characteristics in Parkinsonism: comparison of SWI, T(2)∗maps, T(2)-weighted-, and FLAIR-SPACE. Invest Radiol 2010;45:795-802
33. Péran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423-33
34. Baudrexel S, Nurnberger L, Rub U, et al. Quantitative mapping of T1 and T2∗discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage 2010;51:512-20
35. Jackson JD. Classical Electrodynamics. 3rd ed. New York: John Wiley and Sons; 1999
36. Jin L, Wang J, Zhao L, et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011;134:50-58
37. Hu MT, White SJ, Herlihy AH, et al. A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology 2001;56:1195-200
38. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600
39. Meyer GJ, Schober O, Stoppe G, et al. Cerebral involvement in systemic lupus erythematosus (SLE): comparison of positron emission tomography (PET) with other imaging methods. Psychiatry Res 1989;29:367-68
40. Volkow ND, Rosen B, Farde L. Imaging the living human brain: magnetic resonance imaging and positron emission tomography. Proc Natl Acad Sci U S A 1997;94:2787-88
41. Boska MD, Hasan KM, Kibuule D, et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis 2007;26:590-96
42. Du G, Lewis MM, Styner M, et al. Combined R2∗and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627-32
43. Zhang J, Tao R, Liu C, et al. Possible effects of iron deposition on the measurement of DTI metrics in deep gray matter nuclei: an in vitro and in vivo study. Neurosci Lett 2013;551:47-52
44. Antonini A, Leenders K, Meier D, et al. T2 relaxation time in patients with Parkinson's disease. Neurology 1993;43:697-700
45. Wallis LI, Paley MN, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008;28:1061-67
46. Ulla M, Bonny JM, Ouchchane L, et al. Is R2∗a new MRI biomarker for the progression of Parkinson's disease? A longitudinal followup. PloS One 2013;8:e57904
47. Eapen M, Zald DH, Gatenby JC, et al. Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system. AJNR Am J Neuroradiol 2011;32:688-94